Suzuki, Jun
Hashimoto, Ken
Xiao, Ru
Vandenberghe, Luk H.
Liberman, M. Charles
Article History
Received: 4 November 2016
Accepted: 1 March 2017
First Online: 3 April 2017
Change Date: 22 May 2017
Change Type: Update
Change Details: A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.
Change Date: 22 May 2017
Change Type: Erratum
Change Details: Scientific Reports 7: Article number: 45524; published online: 3 April 2017; updated: 22 May 2017 The authors forgot to cite previous studies relating to in vivo studies in newborn mice. These additional references are listed below as references 1 and 2, and should appear in the text as below. In the Introduction section,
Competing interests
: J.S., K.H., and R.X. have no relevant financial conflicts of interest to declare. L.H.V. holds founder equity in GenSight Biologics, is a consultant to a number of biotech and pharmaceutical companies, and is an inventor on gene therapy patents, including Anc80 which are licensed to various entities. L.H.V also receives sponsored research from Lonza Houston and Selecta Biosciences, licensees of Anc80. L.H.V. has filed a patent application on the use of Anc80 in the cochlea. The study was partly supported by Decibel Therapeutics, and M.C.L has an equity interest in that company.